Pyxis Oncology, Inc. Common Stock
PYXS US7473241013
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-17% | -88% | 30% | -24% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Connealy Pamela Ann CFO |
2.00 USD |
5,450 Bought |
10,900 USD |
26/11/2024 | 26/11/2024 |
Connealy Pamela Ann CFO |
1.96 USD |
83,400 Bought |
163,464 USD |
26/11/2024 | 26/11/2024 |